http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110627909-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 2019-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110627909-B |
| titleOfInvention | Chimeric antigen receptor for specifically activating NK cells and application thereof |
| abstract | The invention relates to the field of biomedicine, in particular to a chimeric antigen receptor specifically optimized for NK cell signal transduction characteristics and application thereof, wherein the chimeric antigen receptor scFv is composed of light chain and heavy chain variable regions and is connected to an NKp44 transmembrane region through a CD8 hinge structure, and an intracellular segment activation signal transduction domain is formed by connecting a CD3 zeta ITAM motif, a 2B4 activation motif, a DNAM1 activation motif and a DAP10 activation motif in series. The chimeric antigen receptor is used for modifying Natural Killer (NK) cells, and the modified NK cells (CAR-NK) can be used for treating tumors positive by tumor specific antigens. In a killing test, compared with a classical third-generation T-CAR structure, the structure obviously enhances the killing capacity of NK cells on tumor cells, and shows good antitumor activity in an in vivo model. |
| priorityDate | 2019-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 582.